CClinicalTrials.gg
CompletedNCT05453721IMPLANE-0529Updated May 7, 2026

Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane(IMPLANE-0529)

An interventional study of Indocyanine green fluorescence imaging method and Modified inflation-deflation method in Segmentectomy and Non-small Cell Lung Cancer Stage I, sponsored by The First Affiliated Hospital of Nanchang University. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by The First Affiliated Hospital of Nanchang University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is a multi-center, prospective, randomized controlled clinical trial. The purpose is to compare the difference of indocyanine green fluorescence imaging method and modified inflation-deflation method in identifying intersegmental plane in segmentectomy, and provide high-level evidence for the selection of intersegmental plane identification method in early NSCLC segmental resection.

Read the detailed description

In patients with early-stage lung cancer, segmentectomy has comparable long-term survival results compared with conventional lobectomy, but patients have a higher postoperative quality of life because more lung tissue is preserved.

Segmentectomy is based on accurate anatomy, and the identification of intersegmental plane is one of the keys to accurate anatomy of segmentectomy.

At present, differential ventilation and differential colorimetry are clinically used to cause the difference between the target segment and the adjacent lung segment to identify intersegmental plane, which both have advantages and disadvantages. Clinical consensus on the best method for intersegmental plane identification has not been formed.

This study is a multi-center, prospective, randomized controlled clinical trial. The study plans to enroll 272 patients with peripheral stage I NSCLC with tumor diameter ≤2cm and consolidation tumor rate \<1. Eligible patients will be randomly divided into the experimental group (indocyanine green fluorescence imaging method) or control group (modified inflation-deflation method) at a ratio of 1:1.

This study is expected to compare the difference of indocyanine green fluorescence imaging method and modified inflation-deflation method in identifying intersegmental plane in segmentectomy, and provide high-level evidence for the selection of intersegmental plane identification method in early NSCLC segmentectomy.

02

Conditions studied

  • Segmentectomy
  • Non-small Cell Lung Cancer Stage I

Keywords

  • Segmentectomy
  • Intersegmental plane identification
  • Indocyanine green fluorescence imaging method
  • Modified inflation-deflation method
03

In context

Carcinoma, Non-Small-Cell Lung

6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,632 are open to participants now.

This study's enrollment of 272 is above the median of 62 across 5,213 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

The First Affiliated Hospital of Nanchang University is the lead sponsor of 26 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Aged 18 to 80 years old;
  2. According to the surgical standards of the Eighth edition of People's Medical Publishing House, patients whose blood pressure was under 160/100mmHg and blood glucose was under 5.6-11.2mmol /L with normal functions of major organs such as heart, lung, liver and kidney before surgery are included. The main criteria are as follows:

    i. Cardiac function examination indicated Goldman index grade 1-2; ii. Pulmonary function examination suggested postoperative predicted FEV1≥40% and DLCO≥40%; iii. Total bilirubin ≤1.5 times the upper limit of normal; iv. Alanine aminotransferase and aspartate aminotransferase ≤2.5 times the upper limit of normal value; v. Creatinine ≤1.25 times the upper limit of normal value and creatinine clearance ≥60ml/min;

  3. The center of the lesion is located in the other lobes except the middle lobe, and in the middle and outer third of the lung;
  4. The maximum diameter of the tumor was not more than 2cm on TLC(Thin layer CT) scan and the clinical stage was cT1a-1bN0M0(according to AJCC staging criteria, eighth edition);
  5. Consolidation tumor rate \<1;
  6. ECOG PSscore 0-1;
  7. All relevant examinations should be completed within 28 days before surgery;
  8. Patients who understand the study and have signed informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Patient with a history of iodine or indocyanine green allergy;
  2. Patient who had received antitumor therapy (radiotherapy, chemotherapy, targeted therapy, immunotherapy) prior to surgery;
  3. Patient with a history of other malignancies;
  4. Patient with secondary primary cancer at enrollment;
  5. Small cell lung cancer;
  6. Prior history of unilateral thoracotomy;
  7. Woman in pregnant or breastfeeding period;
  8. Patient with interstitial pneumonia, pulmonary fibrosis or severe emphysema;
  9. An active bacterial or fungal infection that is difficult to control;
  10. Severe mental illness;
  11. History of severe heart disease , heart failure , myocardial infarction or angina pectoris within the last 6 months;
  12. patient that researcher considers inappropriate to participate in this study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
272 participants (actual)

Study arms

  • Experimental
    Indocyanine green fluorescence imaging method group

    Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy

    Procedure: Indocyanine green fluorescence imaging method

  • Active comparator
    Modified inflation-deflation method group

    Using modified inflation-deflation method to identify intersegmental plane in segmentectomy

    Procedure: Modified inflation-deflation method

Interventions

  • ProcedureIndocyanine green fluorescence imaging method

    Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy

  • ProcedureModified inflation-deflation method

    Using modified inflation-deflation method to identify intersegmental plane in segmentectomy

06

What researchers measure

Primary outcomes

  1. Success rate of intersegmental plane identification

    Successful intraoperative appearance of the intersegmental plane is considered a success

    Time frame: During the operation

Secondary outcomes

  1. Intersegment plane identification time

    Indocyanine green injection/start of ventilation to the first observed intersegment plane appearance

    Time frame: During the surgery

  2. Surgery time

    Time from the beginning to the end of the surgery

    Time frame: During the surgery

  3. Intraoperatve blood loss

    Blood loss during the surgery

    Time frame: During the surgery

  4. Postoperative blood loss

    Blood loss after the surgery

    Time frame: Postoperative in-hospital stay up to 30 days

  5. Postoperative air leakage rate

    Air leakage after the surgery

    Time frame: Postoperative in-hospital stay up to 30 days

  6. Postoperative air leakage time

    time of air leakage after the surgery

    Time frame: Postoperative in-hospital stay up to 30 days

  7. Preoperative pulmonary function

    FEV1.0(forced expiratory volume in 1.0 s)

    Time frame: 1 week before the surgery

  8. Preoperative pulmonary function

    FVC(forced vital capacity)

    Time frame: 1 week before the surgery

  9. Postoperative pulmonary function

    FEV1.0(forced expiratory volume in 1.0 s)

    Time frame: 6/12 months after surgery

  10. Postoperative pulmonary function

    FVC(forced vital capacity)

    Time frame: 6/12 months after surgery

  11. Quality of life(EORTCQLQ-C30)

    Quality of life Scale

    Time frame: 6/12 months after surgery

  12. Adverse event rate

    According to CTCAE-V5.0

    Time frame: Through study completion, an average of 2 year

  13. Adverse event level

    According to CTCAE-V5.0

    Time frame: Through study completion, an average of 2 year

  14. Surgical complication

    According to Clavien-Dindo grading system

    Time frame: Postoperative in-hospital stay up to 30 days

  15. Postoperative 30-day mortality

    Deaths occurring within 30 days after surgery

    Time frame: Within 30 days after surgery

  16. Postoperative 90-day mortality

    Deaths occurring within 90 days after surgery

    Time frame: Within 90 days after surgery

  17. Reoperation rate

    The percentage of patients who need a second operation

    Time frame: Within 30 days after surgery

  18. Number of stapler nail bin used for cutting

    Number of stapler nail bin used for cutting

    Time frame: During the surgery

  19. R0 resection rate

    Negative surgical margin under the microscope

    Time frame: Within 14 days after surgery

Other outcomes

  1. Coincidence rate of intersegmental plane identification

    The shortest distance between the nodule and the cutting edge in all directions in postoperative pathological specimens versus distances measured in preoperative 3D reconstruction in same directions

    Time frame: Within 14 days after surgery

07

Study locations

1 site
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05453721
Lead sponsor
The First Affiliated Hospital of Nanchang University
Collaborators
Dazhou Central Hospital, Ningde Municipal Hospital of Ningde Normal University, First Affiliated Hospital of Gannan Medical University, Fuzhou Pulmonary Hospital of Fujian, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Ningbo No.2 Hospital, Guangdong Provincial People's Hospital, Zhejiang Provincial People's Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Responsible party
Jian Tang (M.D., Ph.D, Professor, The First Affiliated Hospital of Nanchang University) — Principal investigator
First posted
Jul 12, 2022
Start date
Aug 4, 2022
Primary completion
Nov 19, 2024
Completion
Dec 20, 2025
Last update
May 7, 2026

Study contacts

Jian Tang, M.D., Ph.D
principal investigator · The First Affiliated Hospital of Nanchang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion